merckwindow

MSD faces delay in C. diff drug approval as FDA requests more data

pharmafile | July 22, 2016 | News story | Medical Communications, Research and Development |  C diff, FDA, MSD, Merck 

MSD, known as Merck in the US and Canada, has received a setback in its bid to get new C. diff infection treatment, bezlotoxumab, after the US Food and Drug Administration (FDA) requested more data from previously submitted clinical trials.

The additional data and analyses required will not set back the data for final date for approval by three months. The new prescription drug user fee act goal date has been set for October 23rd.

A meeting of the FDA’s antimicrobial drugs advisory committee had voted 10 to 5 to recommend the drug. Bezlotoxumab, a fully monoclonal lg61/kappa antibody, binds to and neutralises C difficile toxin B, which is likely by preventing it from binding to colonic cells and causing their inflammation.

Advertisement

MSD indicates that it looks forward to continuing to work with the FDA on the review for bezlotoxumab.

Sean Murray

Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631_1

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation

Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant

The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …

The Gateway to Local Adoption Series

Latest content